2018. TEDDY

Observ/TNFi exposed newborn/Safety

Retrospective long-term cohort study of children born to women with IBD on antiTNF during pregnancy

- Aim: to compare the RR of severe infections
- Secondary aims: To compare the prevalence of malformations of children exposed to antiTNF compared to those non exposed.
- To compare the prevalence of neoplasm in children exposed to antiTNF and to ascertain the RR of complications

Results:

N: 841

- Severe infections in non-exposed vs exposed children 1.6% vs. 2.8% p-y, HR 1.2 (0.8–1.8), p=ns.
- No differences in: overall proportion of complications 14.9% exposed vs 17.7%; p=0.29
- Proportion of **infections in mothers** treated with antiTNF was higher 4.1% vs 0.9%; p=0.002
- **Complications during delivery** higher in exposed cohort 57.5% s 43.5%; p<0.01
- Children admitted **to intensive care** unit higher in exposed 7% vs 3.1%; p<0.01
- **Low birth weight** higher in exposed 9.8% vs 5%; p<0.01
- No differences in malformations
- **Preterm birth** associated with risk of **severe infection** after birth p<0.001

Conclusions:

In utero exposure to anti-TNF drugs does not seem to be associated with increased short-term or

long-term risk of severe infections in children.

Long-Term Safety of In Utero Exposure to Anti-TNFa Drugs for the Treatment of Inflammatory Bowel Disease: Results from the **Multicenter European TEDDY Study**

Table 5. Factors associated with the risk of severe infection in offspring during follow-up

| | Hazard ratio | 95% confidence interval | P |
|---------------------------|-----------------|----------------------------|-------|
| Exposed (vs. non-exposed) | 1.2 | 0.8-1.8 | 0.3 |
| Preterm delivery | 2.9 | 1.5-5.5 | 0.001 |
| Low birth weight | 0.7 | 0.3-1.6 | 0.4 |
| | | | |

Table 3. Prevalence of complications during pregnancy and delivery and complications affecting newborn's complications

| | Exposed cohort N=388 | Non-exposed cohort N=453 | P |
|--|-------------------------|-----------------------------|-------|
| Complications during preg- nancy (%) | 14.9 | 17.7 | 0.29 |
| Growth retardation | 3.4 | 2.9 | 0.68 |
| Infection | 4.1 | 0.9 | 0.002 |
| Eclampsia | 1.3 | 0.9 | 0.5 |
| Placenta previa | 0.5 | 0.4 | 0.8 |
| Choricamnionitis | 0.3 | 0.4 | 0.6 |
| Abruptio placenta | 5.2 | 6 | 0.61 |
| Delivery-related complica- tions (%)* | 57 | 43 | 0.001 |
| Instrumental delivery | 11.6 | 7.7 | 0.05 |
| Cesarean section | 43.8 | 32 | 0.001 |
| Preterm delivery | 10.6 | 7.3 | 0.09 |
| Newborn complications (%) | 24.5 | 16 | 0.002 |
| Congenital malformations | 5.4 | 2.6 | 0.06 |
| Intensive care unit admission | 7 | 3.1 | 0.009 |
| Low birth weight | 10.6 | 6.8 | 0.05 |
| Low Apgar score | 14.7 | 11.5 | 0.16 |



H